Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Campath-1H in CLL with Residual Disease
NCT00800943Phase 2Unknown
- Sponsor
- Chronic Lymphocytic Leukemia Research Consortium
- Start
- Dec 2003
- Primary completion
- Aug 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by Chronic Lymphocytic Leukemia Research Consortium. Primary endpoints: Elimination of minimal residual disease documented by flow cytometry and Conversion of partial remission to complete remission. Status: unknown.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00800943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00800943.